Evaluating Socioeconomic, Racial, and Ethnic Disparities in Survival Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants.

Allogeneic hematopoietic stem cell transplantation Cancer survival Health disparities Index of concentration at the extremes

Journal

Journal of racial and ethnic health disparities
ISSN: 2196-8837
Titre abrégé: J Racial Ethn Health Disparities
Pays: Switzerland
ID NLM: 101628476

Informations de publication

Date de publication:
01 May 2023
Historique:
received: 21 02 2023
accepted: 21 04 2023
revised: 18 04 2023
pmc-release: 01 11 2024
medline: 1 5 2023
pubmed: 1 5 2023
entrez: 1 5 2023
Statut: aheadofprint

Résumé

This study was undertaken to monitor potential disparities in survival after allogeneic hematopoietic stem cell transplantation (HSCT) with the aim of optimizing access and outcomes for minority and low-income patients. We analyzed 463 patients transplanted over a 72-month study period with a median 19-month follow-up, focused on differences by individual patient race/ethnicity and patients' household income derived from geocoded addresses at the census block group level. Patient sociodemographic and clinical characteristics were abstracted from electronic health records and our HSCT registry, including disease category and status, donor age, transplant type, and conditioning. Approximately, 15% of HSCT patients were non-Hispanic Black or Hispanic with a similar proportion from block groups below the median metropolitan Index of Concentration at the Extremes income score. The overall survival probability was 61.8% at 36 months. Non-Hispanic white (63.6%) and especially Hispanic patients (49.2%) had lower survival probabilities at 36 months than non-Hispanic Black patients (75.6%, p = 0.04). There were no other patient characteristics significantly associated with survival at the p < 0.01 level. The lack of significant differences likely reflects the careful selection of patients for transplants. However, the proportion of minority and low-income patients relative to expected disease prevalence in our area population raises important considerations about which patients successfully make it to transplant. We conclude with recommendations to increase the diversity of patients who receive HSCT by reviewing potential barriers in the transplant referral and selection process and advocating for needed psychosocial and community resources.

Identifiants

pubmed: 37126157
doi: 10.1007/s40615-023-01611-8
pii: 10.1007/s40615-023-01611-8
pmc: PMC10618412
mid: NIHMS1922886
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : U54 CA202995
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA202997
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA203000
Pays : United States

Informations de copyright

© 2023. W. Montague Cobb-NMA Health Institute.

Références

Leuk Lymphoma. 2015 Apr;56(4):987-92
pubmed: 25012944
Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11
pubmed: 37482244
J Racial Ethn Health Disparities. 2017 Dec;4(6):1195-1205
pubmed: 28039602
Biol Blood Marrow Transplant. 2005 Mar;11(3):231-9
pubmed: 15744242
Diabetes Care. 2014;37(5):1279-86
pubmed: 24574350
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Bone Marrow Transplant. 2019 Sep;54(9):1443-1452
pubmed: 30696998
Bone Marrow Transplant. 2012 Nov;47(11):1385-90
pubmed: 22056642
Ann Intern Med. 2020 Feb 18;172(4):229-239
pubmed: 31958813
Cancer Causes Control. 2020 Nov;31(11):1001-1009
pubmed: 32897529
Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182
pubmed: 32438042
Am J Epidemiol. 2017 Oct 15;186(8):990-999
pubmed: 28541384
J Clin Oncol. 2005 Oct 1;23(28):7032-42
pubmed: 16145067
Breast Cancer Res Treat. 2022 Apr;192(2):369-373
pubmed: 34988768
Cancer Res. 2016 Nov 15;76(22):6445-6451
pubmed: 27784742
Biol Blood Marrow Transplant. 2020 Aug;26(8):e173-e174
pubmed: 32417492
Soc Sci Med. 2009 Jun;68(11):1975-84
pubmed: 19359082
Oncologist. 2021 Feb;26 Suppl 1:S15-S16
pubmed: 33351988
Lancet. 2017 Apr 8;389(10077):1453-1463
pubmed: 28402827
J Health Soc Behav. 2002 Sep;43(3):359-81
pubmed: 12467258
J Epidemiol Community Health. 2015 Dec;69(12):1199-207
pubmed: 26136082
Annu Rev Public Health. 2019 Apr 1;40:105-125
pubmed: 30601726
J Clin Oncol. 2003 Oct 15;21(20):3754-60
pubmed: 14551294
Biol Blood Marrow Transplant. 2009 Dec;15(12):1543-54
pubmed: 19896078
Int J Epidemiol. 2018 Jun 1;47(3):788-819
pubmed: 29522187
Epidemiology. 2018 Mar;29(2):207-214
pubmed: 29280853
Blood. 2022 Apr 7;139(14):2212-2226
pubmed: 35061876
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
J Racial Ethn Health Disparities. 2015 Dec;2(4):425-33
pubmed: 26863550
Transplant Cell Ther. 2021 Oct;27(10):869.e1-869.e9
pubmed: 34224915
Cancer. 2022 Dec 15;128(24):4251-4284
pubmed: 36301149
Biol Blood Marrow Transplant. 2015 Aug;21(8):1488-94
pubmed: 25899454
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):275-280
pubmed: 34889386
Blood. 2017 Oct 12;130(15):1699-1705
pubmed: 28724539
J Epidemiol Community Health. 2018 Dec;72(12):1099-1103
pubmed: 30171083
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10
pubmed: 36924931
Du Bois Rev. 2011 Apr 15;8(1):143-157
pubmed: 22518195

Auteurs

Lawrence Garcia (L)

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Joe Feinglass (J)

Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, 750 Lakeshore Dr., 10th Floor, Chicago, IL, 60611, USA. j-feinglass@northwestern.edu.

Hardik Marfatia (H)

Economics Department, Northeastern Illinois University, Chicago, IL, USA.

Kehinde Adekola (K)

Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Jonathan Moreira (J)

Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Classifications MeSH